Manohar Megha M, Campbell Bronwyn E, Walduck Anna K, Moore Robert J
School of Science, RMIT University, Bundoora, Victoria 3083, Australia.
Vaccine. 2022 Sep 22;40(40):5769-5780. doi: 10.1016/j.vaccine.2022.08.059. Epub 2022 Sep 3.
Vaccines are very effective in providing protection against many infectious diseases. However, it has proven difficult to develop highly efficacious vaccines against some pathogens and so there is a continuing need to improve vaccine technologies. The first successful and widely used vaccines were based on attenuated pathogens (e.g., laboratory passaged Pasteurella multocida to vaccinate against fowl cholera) or closely related non-pathogenic organisms (e.g., cowpox to vaccinate against smallpox). Subsequently, live vaccines, either attenuated pathogens or non-pathogenic microorganisms modified to deliver heterologous antigens, have been successfully used to induce protective immune responses against many pathogens. Unlike conventional killed and subunit vaccines, live vaccines can deliver antigens to mucosal surfaces in a similar manner and context as the natural infection and hence can often produce a more appropriate and protective immune response. Despite these advantages, there is still a need to improve the immunogenicity of some live vaccines. The efficacy of injectable killed and subunit vaccines is usually enhanced using adjuvants such mineral salts, oils, and saponin, but such adjuvants cannot be used with live vaccines. Instead, live vaccines can be engineered to produce immunomodulatory molecules that can stimulate the immune system to induce more robust and long-lasting adaptive immune responses. This review focuses on research that has been undertaken to engineer live vaccines to produce immunomodulatory molecules that act as adjuvants to increase immunogenicity. Adjuvant strategies with varying mechanisms of action (inflammatory, antibody-mediated, cell-mediated) and delivery modes (oral, intramuscular, intranasal) have been investigated, with varying degrees of success. The goal of such research is to define adjuvant strategies that can be adapted to enhance live vaccine efficacy by triggering strong innate and adaptive immune responses and produce vaccines against a wider range of pathogens.
疫苗在预防多种传染病方面非常有效。然而,事实证明,针对某些病原体开发高效疫苗很困难,因此持续需要改进疫苗技术。首批成功且广泛使用的疫苗基于减毒病原体(例如,实验室传代的多杀性巴氏杆菌用于预防禽霍乱)或密切相关的非致病生物体(例如,牛痘用于预防天花)。随后,减毒病原体或经改造以递送异源抗原的非致病微生物等活疫苗已成功用于诱导针对多种病原体的保护性免疫反应。与传统的灭活疫苗和亚单位疫苗不同,活疫苗可以以与自然感染相似的方式和背景将抗原递送至粘膜表面,因此通常可以产生更合适的保护性免疫反应。尽管有这些优点,但仍需要提高一些活疫苗的免疫原性。可使用矿物盐、油和皂苷等佐剂来增强注射用灭活疫苗和亚单位疫苗的效力,但此类佐剂不能用于活疫苗。相反,可以对活疫苗进行改造,使其产生能够刺激免疫系统以诱导更强有力和持久的适应性免疫反应的免疫调节分子。本综述重点关注为改造活疫苗以产生充当佐剂以提高免疫原性的免疫调节分子而开展的研究。已经研究了具有不同作用机制(炎症、抗体介导、细胞介导)和递送方式(口服、肌肉注射、鼻内)的佐剂策略,并取得了不同程度的成功。此类研究的目标是确定可通过触发强烈的先天性和适应性免疫反应来增强活疫苗效力并生产针对更广泛病原体的疫苗的佐剂策略。